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EDITORIAL 
Caring for young 
Sinead McGilloway, Michael Donnelly 
"Society...has a choice whether or not to acknowledge the 
importance of the mental health of its children [and young 
people] and invest in it appropriately or not...if we are to 
change things, action is needed now".1 
Recent years have seen an upsurge of interest among 
policymakers, researchers and practitioners - throughout 
the UK and elsewhere - in the growing number of young 
people aged under 25 who are developing mental health 
problems. The research evidence2 indicates that approxi-
mately one in five children and adolescents have mental ill 
health, a figure all the more disturbing in view of further 
evidence suggesting that the majority rarely reach special-
ist services. 
Recently, the Mental Health Foundation1 reported that 
approximately two million young people under 20 in the 
UK have a mental health problem, the range and severity 
of which tends to increase dramatically with age. The 
kinds of problems typically reported include emotional 
and conduct disorders, substance abuse, self harm, eating 
disorders and psychotic illnesses. For example, anxiety and 
disruptive disorders account for approximately 12% and 
10% respectively of all those aged four to 20 years.2 While 
some of these problems are likely to be relatively mild and 
self-limiting, others such as the psychotic and pervasive 
developmental disorders will, if left untreated, pose contin-
uing and potentially more serious problems into 
adulthood. 
Furthermore, one in 100 teenagers in the UK attempt 
suicide and it is now the most common reason for admis-
sion to hospital in this age group. Previous research has 
shown a correlation between attempted suicide and adult-
type depressive illness in young people. ' More recent 
research in Norway has also shown the suicide risk among 
male adolescent psychiatric inpatients to be almost seven 
times higher than in the general population.4 
In addition, an increased risk of premature death among 
the entire adolescent psychiatric inpatient population stud-
ied (n = 1,095) was reported, particularly in the 25-34 
year-old age group. This concurs with recent research 
conducted in Ireland in which the standardised mortality 
ratio for psychiatric inpatients aged 15-35 was almost 100 
times greater than that reported for the general popula-
tion.5 
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Even more worrying, therefore, in the context of these 
findings, is the potentially significant contribution of 
mental ill health and possible subsequent hospitalisation 
to the increase in suicidal behaviour and growing suicide 
rate particularly (but not exclusively) among young men, 
about which there has been considerable and growing 
concern in recent years/"8 
According to local practitioners in Northern Ireland, 
mental health services are under-resourced when compared 
to the rest of the UK and youth mental health services, in 
particular, are in urgent need of funding and/or re-organi-
sation. This is perhaps most apparent in the acute shortage 
of specialist provision for vulnerable young people over 14 
which, at present, comprises a single, regional, six-bed 
inpatient and outpatient unit located in Belfast (the Young 
People's Centre (YPC)). Reports from local practitioners 
indicate an over-subscription of places to the YPC and a 
waiting list for admission. Last year, the Department of 
Health in London allocated £20 million to improve 
services for young people, a sizeable chunk of which is 
likely to be secured for mental health service provision, 
particularly following recent reports by prestigious bodies 
such as the Health Advisory Service (HAS)' and the 
Mental Health Foundation.1 
Unfortunately, the kind of ring-fenced funding which 
may be required to meet the mental health needs of young 
people in Ireland is less forthcoming despite a rapidly 
developing policy agenda. Each of the four Health and 
Social Services Boards in Northern Ireland has undertaken 
a review of, or is in the process of reviewing, youth mental 
health services. 
Completed reviews acknowledge the need for rapid 
change in service organisation and delivery particularly for 
those young people moving into their teens. The reports 
highlight, above all, the importance of adopting the four-
tier model of care advocated by the Health Advisory 
Service and, in turn, by other key bodies and committees 
including the Mental Health Foundation' and the Audit 
Commission."1 
Briefly, this 'template' of mental health service provision 
for young people describes a strategic approach to 
commissioning and delivering a comprehensive and fully 
integrated child and adolescent mental health service 
which straddles four pivotal levels or 'Tiers' of provision. 
Tier one services comprise, in large part , primary care 
professionals, amongst whom the GP is probably best 
placed to recognise the early symptoms of mental illness. 
Tier two services refer to direct mental health interventions 
by individual professionals. Services at Tier three, on the 
other hand, are more specialised and provided by multi-
disciplinary teams to assess and treat at-risk groups such 
as those with eating and developmental disorders. These 
teams, in turn, act as gatekeepers to Tier four services 
which include specialist inpatient and secure provision for 
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young people with highly specific and complex needs. Tier 
four professionals are tasked with providing advice and 
support to professionals in the other three tiers of provi-
sion while links between and within Tiers one and two 
may be developed and strengthened by the work of desig-
nated primary mental health workers. According to the 
HAS, the implementation of the model should be guided 
by the values and principles (eg. comprehensiveness, inte-
gration and development/change) which underpin any high 
quality service development.' 
This model, or parts thereof, have been implemented in 
Great Britain through, for example, the appointment of 
primary mental health workers. Following its policy state-
ment on the way forward for child and adolescent mental 
health services in Northern Ireland," the Department of 
Health and Social Services has recently indicated that it is 
planning to undertake a review of psychiatric hospital 
provision for adolescents (personal communication). The 
Irish government has gone further by stating its intention 
to provide 'approved centres' for the care and treatment of 
children with mental disorders.'2 
The most recent figures show that 130 children and 
young people aged under 16 (ie. 0.5% of all admissions) 
were admitted to psychiatric inpatient care in Ireland 
during 1998, although this represents a substantial reduc-
tion from the 203 admissions during the previous year." It 
is notable that under the Mental Health Act (1995) in the 
south of Ireland (unlike Northern Ireland), anyone under 
the age of 16 should not be 'detained' in adult psychiatric 
inpatient units. 
There is a strong focus on Tier four services in both 
jurisdictions. Youth mental health care is an area where an 
all-Ireland or cross-border approach has the potential to 
generate important lessons for policy and service provi-
sion. Our research has shown an increasing trend in 
admissions of young Northern Irish teenagers (under 18) 
to adult psychiatric inpatient care between 1989 and 
1995.H In addition, we found that almost one in five of 
under 18 admissions (86/443, 19%) were aged under 16 
when first admitted to adult wards during this six-year 
period. Moreover, recent census-based research under-
taken in Northern Ireland has shown an increase of 3 3 % -
between the years 1981 and 1991 - in psychiatric bed 
occupancy among young men aged 15-24 years." 
Importantly, the recent draft policy statement by the 
DHSS (NI) states, among other things, that "...children 
and adolescents should not be accommodated together or 
with adul ts ."" Undoubtedly, the full implementation of 
well-integrated Tier one and Tier two services - with their 
emphasis on early detection and treatment - would go a 
long way toward preventing and/or reducing admissions 
to hospital (particularly an adult psychiatric ward) for 
young people with more serious mental health needs. 
Therefore, strategic efforts to improve the highly 
specialised Tier four services in both the north and south 
of Ireland ought to be accompanied by simultaneous 
attempts to address services at the other three levels partic-
ularly with respect to early detection and prevention. 
Most important of all, perhaps, is the need to develop: 
successful intra- and inter-agency working between special-
ist mental health services and primary and community 
care-based professionals; closer co-operation between 
adult and youth mental health services; and effective part-
nerships between individual mental health (and other) 
professionals and parents/carers and young people. For 
example, the direct and active collaboration of GPs with 
local child and adolescent service providers might help to 
improve the generally low level of detection and recogni-
tion of child and adolescent psychiatric disorder in primary 
care settings. The severity of symptoms in a young 
teenager may be underestimated and/or less well recog-
nised by healthcare professionals than in adults with 
mental ill health because "things are not always as they 
seem"."' Thus, distress in a young teenager may present as 
a normal reaction to exam pressures or may be due to a 
complex psychosocial and clinical problem. Community 
mental health teams and, in particular, adult psychiatrists 
may - as suggested by Fitzgerald,17 - play an important 
preventive role by adopting a more holistic and 'user-
friendly' approach encompassing the treatment of both 
parents and their children. 
In addition, those involved in the lives of young people 
(eg. parents, carers) act as an initial 'filter' to Tier one 
services and their role, therefore, in recognising early 
symptoms of mental ill health and possible suicidal behav-
iour cannot be under-estimated. Consequently, the 
implementation of parental training and awareness pack-
ages through the health or education sector (or both) 
ought to receive serious consideration. 
Arguably, the resource implications of changes in youth 
mental health service provision may be significant and any 
potentially innovative service responses might well be 
stymied by the considerable uncertainty surrounding the 
extent to which it might be possible to implement the four-
tier model within available resources. However, it should 
be possible to carry forward at least some of the HAS 
recommendations (eg. those related to information, aware-
ness and training) within existing funds and staffing 
arrangements. 
Recent political cross-border developments provide an 
important and timely opportunity to explore the possibil-
ities for comparative and collaborative work on youth 
(and adult) mental health within the two jurisdictions. For 
example, the establishment of a national forum or several 
regional fora would, in the first instance, facilitate shared 
learning between health boards, Trusts and primary care 
and specialist mental health professionals with respect to 
the planning, development and delivery of the full range of 
youth mental health services. 
Collaborative research is required to examine the preva-
lence, nature, detection and treatment of psychiatric 
disorder in young Irish people. The benefits or otherwise 
of hospitalisation both in specialised and adult psychiatric 
settings also merit investigation. More specifically, further 
audit and research ought to be conducted in order to: 
• translate a locally suited version of the the four-tier 
model taking account of factors such as rurality, avail-
able resources and the economic consequences of service 
configuration 
• help identify 'at-risk' populations and gaps in service 
provision 
• elicit the experiences and views of young people with 
mental ill health and their parents/carers (despite the 
well known difficulties in recruiting young research 
participants) 
• evaluate and disseminate preventive and other models of 
good practice in youth mental health. 
Local commissioners and service providers ought to be 
willing to take on board the results emanating from this 
kind of research. However, ". . . the root of the difficulty in 
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applying research findings to improve services is that the 
services are mostly not conceived of as a system of care. 
Thus, if mental health is the desired outcome, we can only 
hope to achieve it if services are planned and enabled to 
work together as a system with this common aim".ls 
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